Eton Pharmaceuticals (ETON) director Adams received 10,000 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Jennifer McKie Adams (director at Eton Pharmaceuticals Inc., ETON) reported that they received 10,000 shares on Jul 31, 2026.
- Reporting person
- Adams Jennifer McKie
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Grant or award (A) | Common StockOn 10,000 Common Stock1 | +10,000 | - | - | 10,000 direct |
Holdings before and after
- Common Stock: 0 to 10,000 direct
Footnotes from the filing
- 1. On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Adams report in this ETON Form 4?
Jennifer McKie Adams (director at Eton Pharmaceuticals Inc., ETON) reported that they received 10,000 shares on Jul 31, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for ETON
Across the 20 sessions after earlier ETON headlines, the stock closed higher 13 times and lower 7 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ETON | SPY |
|---|---|---|---|
| Aug 3, 2026 | Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 | -2.8% | +1.4% |
| Jul 29, 2026 | Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution | +3.2% | -1.5% |
| Jul 17, 2026 | Canaccord Genuity initiated coverage on Eton Pharmaceuticals with a new price target | +13.8% | -1.0% |
| May 20, 2026 | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) | +4.7% | +1.0% |
| May 15, 2026 | Eton Pharmaceuticals Reports First Quarter 2026 Financial Results | +1.0% | -1.2% |
| May 13, 2026 | Eton Pharmaceuticals to Participate in Upcoming Investor Conferences | +3.7% | +0.6% |
Earlier insider filings at ETON
- Jul 17, 2026Amendment: Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)
- Jul 16, 2026Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)
- Jul 14, 2026President & CEO Brynjelsen Sean exercised 227,500 shares at a strike of $1.20, increasing direct ownership by 27% to 1,061,194 units (SEC Form 4)
- Jul 13, 2026Chief Business Officer Krempa David converted options into 10,000 shares, increasing direct ownership by 37% to 37,025 units (SEC Form 4)
- Jul 7, 2026Large owner Opaleye Management Inc. sold $4,768,637 worth of shares (126,685 units at $37.64) (SEC Form 4)
Keep researching ETON
- ETON insider tradesEvery buy and sale reported by Eton Pharmaceuticals Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- ETON earnings historyPast Eton Pharmaceuticals Inc. earnings releases, newest first.
- ETON financial statementsRevenue, profit, cash flow and balance sheet from Eton Pharmaceuticals Inc.'s SEC filings.
Quantisnow market dataNASDAQ
ETON
Eton Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for ETON
Full ETON profile on Quantisnow Follow ETON and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time